We took some time to discuss this recent article which is very timely and it compared weight loss response and changes in cardiometabolic risk markers in postmenopausal women using semaglutide with and without menopause hormone therapy (HT) use. In postmenopausal women with overweight or obesity treated with semaglutide, HT use was associated with an improved weight loss response. It was a small study size of 60 women but nonetheless good data. Larger studies should be conducted to confirm these results.

Article: https://pubmed.ncbi.nlm.nih.gov/38446869/
To Follow US check out:
Heather- www.theshowcenter.com
Jackie- https://www.mymonarchhealthco.com
The podcast- @justaskhive
Heather- @showcenterdrq
Jackie- @jackiep_gynnp
Tara @thesexualhealthpharmacist

The course is live and available at:
the-hive8.teachable.com